Researchers at Stanford University School of Medicine and Intel Corporation have created a novel silicon chip that can help identify people with a particularly severe form of lupus.
To help identify biomarkers of early lupus, the researchers aimed to establish a relationship between levels of specific autoantibodies and the evolution of clinical signs of lupus over time.
The researchers hoped to learn about second pregnancy outcomes in women with lupus, particularly in those whose first pregnancy had an adverse outcome.
Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.
A study published in a recent issue of the journal Lupus characterizes a new potential biomarker of fatigue in people with lupus.
People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.
People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.
The researchers hoped to determine whether children with lupus have worse academic functioning relative to their peers of similar demographic and socioeconomic background.